Cytoskeletal myotoxicity from simvastatin and colchicine

We report the case of a 79‐year‐old man with mild chronic renal failure who developed severe rhabdomyolysis after combined exposure to simvastatin and colchicine. Colchicine induces myopathy through disruption of microtubular function with subsequent vacuolization and pseudomyelinic body accumulation. Statin therapy is associated with myonecrosis, membranous myeloid bodies, and vacuolization, presumably as a function of impaired isoprenoid metabolism. Vesicle trafficking requires small G‐protein prenylation and statins can disrupt cytoskeletal integrity. We propose that synergistic cytoskeletal myotoxicity may account for the extreme elevation of serum creatine kinase not previously reported in pure colchicine myopathy. Muscle Nerve, 2004

[1]  S. Craig,et al.  Exocytotic "constipation" is a mechanism of tubulin/lysosomal interaction in colchicine myopathy. , 2003, Experimental cell research.

[2]  T. Ohm,et al.  Blockade of HMG‐CoA reductase activity causes changes in microtubule‐stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease , 2003, The European journal of neuroscience.

[3]  H. Chiu,et al.  Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. , 2002, Clinical neuropharmacology.

[4]  D. Figarella-Branger,et al.  Colchicine myopathy: a vacuolar myopathy with selective type I muscle fiber involvement , 2002, Acta Neuropathologica.

[5]  H. Shibasaki,et al.  Accumulation of microtubule-based motor protein in a patient with colchicine myopathy , 2000, Neurology.

[6]  J. Vockley,et al.  Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. , 2000, Molecular genetics and metabolism.

[7]  P. Meek,et al.  Fatal colchicine overdose: report of a case and review of the literature. , 1998, The American journal of emergency medicine.

[8]  R. Gregg,et al.  HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. , 1997, Toxicology and applied pharmacology.

[9]  R. Laaksonen,et al.  Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short‐term simvastatin treatment in humans , 1995, Clinical pharmacology and therapeutics.

[10]  D. Sackett,et al.  Molecular mechanism of colchicine action: induced local unfolding of beta-tubulin. , 1993, Biochemistry.

[11]  A. Engel,et al.  Experimental Lovastatin Myopathy , 1993, Journal of neuropathology and experimental neurology.

[12]  C. Côté,et al.  Cytoskeletal structure of skeletal muscle: identification of an intricate exosarcomeric microtubule lattice in slow- and fast-twitch muscle fibers. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[13]  C. Laezza,et al.  Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells , 1993, Journal of cellular physiology.

[14]  R. Kuncl,et al.  Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. , 1991, The Journal of rheumatology.

[15]  R. Kuncl,et al.  Chronic human colchicine myopathy and neuropathy. , 1988, Archives of neurology.

[16]  M. Rogawski,et al.  Colchicine myopathy and neuropathy. , 1987, The New England journal of medicine.

[17]  L. Gutmann,et al.  Chronic human colchicine neuropathy and myopathy. , 1986, Archives of neurology.

[18]  P. Slotwiner,et al.  THE FINE STRUCTURE OF SPHEROMEMBRANOUS DEGENERATION OF SKELETAL MUSCLE INDUCED BY VINCRISTINE , 1967, Journal of neuropathology and experimental neurology.

[19]  P. Slotwiner,et al.  Spheromembranous degeneration of muscle induced by vincristine. , 1966, Archives of neurology.

[20]  H. Kontos.  Myopathy associated with chronic colchicine toxicity. , 1962, The New England journal of medicine.

[21]  K. Downing,et al.  Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. , 2000, Annual review of cell and developmental biology.

[22]  F. Vrtovsnik,et al.  [Inhibitors of HMG CoA reductase: new modes of action, new indications?]. , 2000, Therapie.

[23]  A. Doğukan,et al.  Colchicine toxicity. , 1999, Clinical nephrology.

[24]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[25]  K. Kaibuchi,et al.  Small GTP-binding proteins. , 1992, International review of cytology.